5-羟色胺3拮抗剂BRL 43694不会损害顺铂对荷瘤小鼠的疗效。
The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice.
作者信息
Goddard P M, Jones M, Pollard L A, Valenti M R, Harrap K R
机构信息
Drug Development Section, Institute of Cancer Research, Sutton, Surrey, U.K.
出版信息
Cancer Chemother Pharmacol. 1990;25(5):377-9. doi: 10.1007/BF00686242.
PMID:2155065
Abstract
Binary combinations of cisplatin and the 5-HT3 antagonist, BRL 43694, have been used to treat both conventional mice bearing either L1210 leukaemia or ADJ/PC6 plasmacytoma and nude mice xenografted with a human ovarian carcinoma (HX/110). In no case was there evidence for antagonism by the antiemetic of the antitumour properties of cisplatin.
摘要
顺铂与5-羟色胺3拮抗剂BRL 43694的二元组合已用于治疗携带L1210白血病或ADJ/PC6浆细胞瘤的传统小鼠以及移植了人卵巢癌（HX/110）的裸鼠。在任何情况下，都没有证据表明止吐药会拮抗顺铂的抗肿瘤特性。
Zotero 插件